Navigation Links
Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
Date:2/3/2009

VENLO, Netherlands, Feb. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its fourth quarter and year-end 2008 financial results call. The Webcast will take place at 9:30 a.m. EST on Tuesday, February 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

    What:     Webcast of QIAGEN's fourth quarter and year-end 2008 financial
              results call

    When:     9:30 a.m. EST on February 10

    Where:    The Webcast is accessible at www.qiagen.com/goto/ConferenceCall

    How:      Log on to the Web at the address above

              The corresponding presentation slides are available for download
              in the investor relations section of QIAGEN's Web site at
              www.qiagen.com/goto/ConferenceCall.

    Contact:  Andreas Marathovouniotis, Russo Partners, (212) 845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webmaster@vdat.com.)


'/>"/>
SOURCE QIAGEN N.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
2. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
3. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
6. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
7. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
8. Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
10. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
11. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Men who have ... levels had a positive association with increased prostate growth or benign prostatic hyperplasia, ... Neurourology Journal involved 571 Korean men who underwent urological examinations, including serum ...
(Date:1/24/2017)... /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ... active lead drug candidate, PBI-4050, has been issued a ... and Healthcare Products Regulatory Agency ("MHRA") for the treatment ... designation is an early indication that a medicinal product ... Medicines Scheme ("EAMS"), intended for the treatment, diagnosis or ...
(Date:1/24/2017)... Jan. 23, 2017  Recognizing the need to ... discovery and solutions, the University of Miami announced ... for Science and Engineering to achieve those milestones ... to help solve some of the world,s most ... Julio Frenk unveiled the network of ...
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
Breaking Biology Technology:
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):